Abstract:825 October 2014 O are currently the most versatile analgesics, making them the drugs of choice for moderate to severe pain associated with invasive procedures, cancer, and various other chronic disease states. However, there is a large interindividual response to the analgesic effect of opioids and a relatively narrow therapeutic index.1 Genetic factors contribute to the differential response to opioids by regulating their pharmacokinetics (metabolizing enzymes and transporters) and pharmacodynamics (receptors and signal transduction).2 The μ-opioid receptor (OPRM1) A118G single nucleotide polymorphism has been a major focus of research into the pharmacogenetics of opioid response. Emerging knowledge regarding the molecular mechanisms regulating pain in animal models has increased the hopes of identifying personalized pain therapies.3 In vitro experiments show that variant receptors are associated with higher binding affinity to and potency of the endogenous ligand, β-endorphin, but lower What We Already Know about This Topic

OPRM 1 A 118 G Gene Variant and Postoperative Opioid Requirement